U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

pSivida Corp. (PSDV)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.25+0.03 (+2.46%)
At close: 4:00PM EDT
People also watch
ALIMOPXAPRANRPRXBDSI
  • G
    Gary
    Gary
    i have flatulence watching this stock trade ...psti up nicely, vblt up nicely, alny surges, blue up nicely, sphry doing great, kite bought for premium ....and psdv? more of the usual ..continued downward spiral ............. at least alim hanging in there .....mz. lurker, pls wake up - have a cup of coffee or something - take some no-doze ...your stock is tanking ...do "something" ..
  • A
    Anonymous
    Anonymous
    Does anyone know? Under the new terms in which PSDV receives income from ALIM, will that not be credited to their earnings until the 2nd quarter instead of the present quarter?
  • O
    Olivia
    Olivia
    The trading setup for PSDV looks very enticing. awe-som*sto-cks just allerted a new stock - it beats having to dig online yourself for new stock ideas.
  • M
    Mick
    Mick
    As a very long term shareholder of pSivida, I've seen evaluation agreements come and go. They leave the room only after years of "nothing happening". It is never announced that they've left the room. I recall P. Ashton speaking of potential partners with Tethadur on his last conference call...yeah, the next day he was fired. So, is it possible that the "pending collaborations" are ghosts of Christmas past? You bet. But we are all hoping that Nancy is bringing more focus to pSivida management. And lets face it, the Durasert platform has two very good indications in the books that will take market share from large pharma drugs. More importantly, the combined MC's of Alimera and pSivida are still less that 150Million; that's pharma chump change.
    I'm hoping that pSivida finds a way to partner up with OA Durasert and sells off it's Durasert ophthalmology gig with an Alimera acquisition. I'm not sure how to value Durasert OA, but my guess is that it's going to work very well, much like micro-dosing
    chronic and difficult to treat diseases of the back of the eye. We will get some news on that by the end of November or early December. Perhaps with a collaboration agreement to boot. I have many regrets about holding the stock of this company. If I only sold all of my holdings with every pop, then purchased it all back after it's inevitable fall......I would have been in much better shape than I am today. The evaluation agreements have yet to materialize into collaboration agreements. Let's hope that changes with the one year anniversary of Nancy's and Deb Jorn's arrival. This MB has been dead for these reasons, we're all kind shell shocked.
  • j
    jim
    jim
    An Oncosil Pancreatic Cancer Clinical Trial #NCT03003078 was started in March 2017 and is scheduled for completion in February 2020. PSDV has an 8% royalty and an annual $100,000 license maintenance fee. Its curious I wasn't able to find any mention of Oncosil at the PSDV website, but it has been included in the 10-K's. I understand that in the past PSDV has sought to downplay the potential of Oncosil.
  • M
    Mick
    Mick
    Although we've received zero information on the pending PI Hospital for Special Surgery implant that delivers Dexamethasone
    for severe OA. I am intrigued by the potential regulatory pathway that may accompany a potential filing with the FDA. Dex is well understood by the FDA as a drug used in OA. It's injected in the knee with limited success in patients, as it just doesn't last very long, like 30 days or less. So, an implant for severe OA delivering Dex on a sustained ( 1yr.) basis might be well received by the FDA. I find the initial PI trial by HSS curious. There are only 6 patients in the initial study, small to say the least. So, is it possible that the FDA and HSS have recognized that should the SR implant be effective (and HSS is the investigator sponsor) , perhaps the regulatory pathway may be simplified. Dexamethasone is a well understood, off patent drug. Perhaps an expedited 505(b)2
    pathway was considered by HSS and pSivida from the outset of the implant. In this pathway, data from all previous regulatory filings may be used to bolster a new application. For those that have not heard of this FDA pathway to approval, it's good to review it:
    The 505(b)(2) application is one of three established types of new drug application
    (NDA), and it is a pathway to approval that can potentially save pharmaceutical sponsors
    both time and money. However, many sponsors are unsure how to evaluate the possible
    benefits of using this type of application.
    The 505(b)(2) regulatory pathway is defined in The Federal Food Drug and Cosmetics
    Act as an NDA containing investigations of safety and effectiveness that are being relied
    upon for approval and were not conducted by or for the applicant, and for which the
    applicant has not obtained a right of reference. These applications differ from the typical
    NDA (described under Section 505(b)(1) of the Act), in that they allow a sponsor to rely,
    at least in part, on the FDA’s findings of safety and/or effectiveness for a previously
    approved drug (the “reference drug”). Section 505(b)(2) was added to the Act in 1984
    with the goal of avoiding unnecessary duplication of preclinical and certain human
    studies. However, the sponsor must still provide any additional preclinical or clinical
    data necessary to ensure that differences from the reference drug do not compromise
    safety and effectiveness. The 505(b)(2) NDA also differs from an abbreviated NDA
    (ANDA; described under Section 505(j) of the Act), which is an application containing
    information to demonstrate that the proposed product is identical to a previously
    approved product. Identity is proven in an ANDA simply through chemistry and
    bioequivalence data, without the need for preclinical and clinical trials assessing safety
    and efficacy. In a sense, a 505(b)(2) application can be thought of as a hybrid that
    contains more data than an ANDA, but less data than an NDA.
  • S
    Shah
    Shah
    This was a very strong conference presentation. The biggest call option on the stock that could make this a 10 -20 stock is, as one analyst noted in the Q and A is PSDV osteoarthritis product. And she was very positive about the scoring method and when the IND data will come out.
    People did not dig deep, and in a week or two once they do this stock can really skyrocket. Also, the CEO said she is positive about securing additional partners this year, and is already on the hunt for it plus positive news coming on the key trials.
  • G
    Gary
    Gary
    SPHRY up 16% today ...over $9 and change ... bought more shares today to increase my position ...positive news on cancer front for this little known Australian stock...market cap now close to $350M ... I posted about it previously when I t was $5 and change ...check it out ...as always, do your DD ... it's my largest position ..I like it's odds .... as well as the successful vivagel ph III results that they announced earlier ...glta
  • S
    Shah
    Shah
    After market high was 1.56, a short's attempt to paint the tape with small trade at 1.19 notwithstanding. Most trades are between 1.40 - 1.50. Will close above 1.50 tomorrow.
  • G
    Gary
    Gary
    Hey, Mzzzz Lurker, -you forget that you work for shareholders -pls do us all a favor and sell PSDV to ALIM -
  • A
    Alfred
    Alfred
    PSDV reports earnings on Monday. Any positive news should move the stock higher. No new news means we will continue to go sideways until FDA filing is made. I am hoping for new news but will continue to wait at these low stock price levels. Glad to pick up more shares cheaply if sellers try to push the stock down again based on no news.
  • A
    Alfred
    Alfred
    Quickly get out why you can. I could barely stand to hear the conference call. The shorts are piling in to drive the stock to zero. Whoo is me.
  • T
    Tick tock timer
    Tick tock timer
    FDBL had 100 million shares traded in under 30 minutes today.
  • D
    Desi
    Desi

    Found a great no fee daytrading newsletter, vist www.PennySt0ckl0l.org and sign up...so glad I did

    Loading...
    www.PennySt0ckl0l.org
  • A
    Alfred
    Alfred
    Still a waiting game for positive stock price moving news. Will it be this reporting period (in 10 days) or the beginning of next year? No doubt that FDA submission will be reported by January 2018. Possibly we could hear of another collaboration effort. We are building a nice trend up off the recent lows. The almost 3% short interest is going to have to pay up big when the stock soon begins to move. Not a lot of stock to trade available when they try to cover.
  • A
    Alfred
    Alfred
    Hmmmm? Could we have hit the lows for PSDV? Are the shorts scrambling yet? I tried to buy all I could get at close to a buck a share. Not a lot of sellers were trying to get out at those levels (low volume).
  • A
    Alfred
    Alfred
    A reminder that in less than 3 weeks, PSDV will deliver an earnings report. Generally, they like to provide positive accomplishments and news that hopefully this time will move the stock to a higher level.
  • A
    Alfred
    Alfred
    To put things in perspective, less than 1% of the shares are trading. This small amount of trading is not confirming a negative price trend that I am concerned about. If large amounts of sellers were bailing, then I might pay attention. I keep putting in buy orders at these low prices and much of the time I only get partial fills. Tells me sellers are reluctant to give up at these low levels.
  • A
    Alfred
    Alfred
    Short interest is up for no reason. All news is positive and just a matter of time before price moving results are reported. Nothing for me left to do but keep buying at these low prices and wait!
  • B
    BioLover
    BioLover

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.